Please ensure Javascript is enabled for purposes of website accessibility

Accelerate Diagnostics Announces Emergency Use Authorization for Covid-19 Antibody Test

By Taylor Carmichael - Aug 19, 2020 at 9:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This new testing platform will speed up health checks by determining whether asymptomatic people have COVID-19 antibodies in 30 minutes.

Accelerate Diagnostics (AXDX -1.40%) is a biotech company that is focused on accelerating diagnostic speeds for bacterial and fungal infections that lead to sepsis, one of the leading causes of death. After the COVID-19 pandemic broke out, it signed a collaboration agreement with a small private biotech, BioCheck, that had developed a fast and automated diagnostic that was capable of testing human serum for the presence of antibodies to the novel coronavirus and returning a result in 30 minutes.

On Tuesday, the two companies announced that the Food and Drug Administration had granted an emergency use authorization (EUA) for the new test. Accelerate Diagnostics has the rights to distribute the testing system in North America, Europe, and the Middle East. BioCheck's test is performed on the Sophonix MS-Fast system, also distributed by Accelerate Diagnostics and given approval under the EUA.

MS-Fast diagnostic system

Image source: Accelerate Diagnostics

This new diagnostic targets the S1 protein, also known as the spike protein, which is the major antigen of the coronavirus. As Shelley Campeau, manager of clinical trials for Accelerate Diagnostics, said in the company's press release: "The S1 protein has the fewest similarities to other coronaviruses, which allows for a lower probability of false positives due to cross reactivity. The S1 protein is also the primary target for the leading COVID-19 vaccines candidates, which are being developed to neutralize antibodies that can block the virus from infecting healthy cells."

Added Accelerate CEO Jack Phillips: "This EUA will allow for more widespread adoption of the MS-Fast serology-based COVID-19 antibody testing platform."

The stock rose almost 10% in after-hours trading. However, in early trading Wednesday, it fell back, and as of 10:27 a.m. EST was down by 5.5%.

{%sfr%)

Taylor Carmichael owns shares of Accelerate Diagnostics. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Accelerate Diagnostics, Inc. Stock Quote
Accelerate Diagnostics, Inc.
AXDX
$2.12 (-1.40%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.